1. Home
  2. Our Firm
  3. News
  4. Guggenheim Partners Announces Closing of $1 Billion Collateralized Loan Obligation Transaction

Our Firm

November 18, 2011

Guggenheim Partners Announces Closing of $1 Billion Collateralized Loan Obligation Transaction

Placed by Citigroup, "5180 CLO" is the Largest Collateralized Loan Obligation Issued to Date During 2011

NEW YORK – Guggenheim Partners, LLC ("Guggenheim"), a diversified financial services firm, announced the closing of a $1,043,000,000 collateralized loan obligation transaction ("5180 CLO" or the "transaction").

The CLO, named "5180 CLO LP", will invest in a diversified portfolio consisting primarily of senior secured bank loans. It is the largest CLO issued in 2011 year-to-date and one of the largest arbitrage CLOs issued since the inception of the market. The transaction comes at a time when yield spreads on many of the underlying securities are near the widest levels since December 2009*.

"We believed this was an opportune time to acquire collateral and we had strong support from the investor community,” said Todd Boehly, president of Guggenheim Partners. “The 5180 CLO transaction exemplifies our commitment to utilizing innovative solutions to unlock value for investors.  We are pleased to have partnered with Citigroup and our clients on this transaction."

5180 CLO will be managed by Guggenheim Investment Management, LLC ("GIM"), an affiliate of Guggenheim Partners. Prior to this transaction, Guggenheim Partners, on behalf of GIM, was awarded "2011 CLO Manager of the Year" in the United States by Creditflux. Details of 5180 CLO's various tranche sizes, ratings, and coupons can be found in the table below:

5180 CLO LP Capital Structure
Class A-1 Notes        
Aaa / AAA
        $600,000,000         L + 1.75%
Class A-2 Notes         NR / AA         $63,650,000         L + 3.20%
Class B Notes         NR / A         $11,635,000         L + 4.50%
Class C Notes         NR / BBB         $64,250,000         L + 6.20%
Class D Notes         NR / BB         $48,150,000         L + 8.65%
Income Notes        
        $120,500,000         --

*According to data compiled by Bloomberg: http://www.bloomberg.com/news/2011-11-02/citigroup-said-to-sell-1-billion-clo-for-guggenheim-investment.html


Certain statements made by Guggenheim Partners (the “Company”) in this release are forward-looking. The Company’s actual future results may differ significantly from those anticipated in any forward-looking statements due to numerous factors. These include, but are not limited to, the effects of the substantial competition in the investment management business, including competition for access to brokerage firms’ retail distribution systems, the Company’s reliance on revenues from investment management contracts which renew annually, regulatory developments, accounting pronouncements, and other additional risks and uncertainties as set forth in the Company’s filings with the SEC. The Company undertakes no responsibility to update publicly or revise any forward-looking statements.

This is not an offer to buy or sell, or a solicitation of an offer to buy or sell any security or fund interest.  Any investment decision to invest  must be made based on the offering materials, which will contain additional information about the investment objectives, terms and conditions of an investment and will be subject to the terms and conditions contained in such offering materials. Investors should consider the investment objectives and policies, risk considerations, charges and expenses carefully before investing. Investors should read the offering materials carefully before they invest.

Member FINRA/SIPC (9/11)


March 19, 2018

Michael Schmidt to Join Guggenheim Securities as Biotech Analyst

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Michael Schmidt, Ph.D. will join the firm in June as a Senior Analyst and Senior Managing Director in a planned expansion of the firm’s Healthcare Research team. Dr. Schmidt will focus on the coverage of Biotech companies, working closely with our growing therapeutics team.

Read More

February 21, 2018

Guggenheim 1Q Fixed-Income Outlook: Upgrading Quality and Shortening Duration Amid Late-Cycle Behavior in Bond Markets

NEW YORK, NY – Guggenheim Investments, the global asset management and investment advisory business of Guggenheim Partners, today provided its First Quarter 2018 Fixed-Income Outlook, “Walking the Risk Tightrope.”

Read More

January 24, 2018

Guggenheim Investments Appoints Brian E. Binder as Chief Administrative Officer

NEW YORK – Guggenheim Investments, the global asset management and investment advisory division of Guggenheim Partners, announced today that Brian E. Binder has been appointed as a Senior Managing Director and Chief Administrative Officer. He is based in Guggenheim’s Chicago office.

Read More

© 2018 Guggenheim Partners, LLC. All rights reserved. Guggenheim, Guggenheim Partners and Innovative Solutions. Enduring Values. are registered trademarks of Guggenheim Capital, LLC.